Display Settings:

Format

Send to:

Choose Destination
    Vet Clin North Am Equine Pract. 2003 Dec;19(3):791-806.

    Treatment and prevention of intestinal parasite-associated disease.

    Source

    Division of Equine Clinical Studies, Faculty of Veterinary Medicine, University of Glasgow, Bearsden Road, Glasgow, Scotland G61 8QH, UK. s.love@vet.gla.ac.uk

    Abstract

    Since 1917, only 11 new endoparasiticides have been developed for the horse, of which five chemical classes are in common use. The selection pressure of frequent administration of deworming doses for parasite control programs has been associated with the development of resistance of small strongyle parasites to the effects of benzimidazoles and pyrantel salts. Against the background of the inevitability of the occurrence of ivermectin/moxidectin resistance, responsible use of equine anthelmintics based on the clinical pharmacology of the compounds and the biology/epidemiology of intestinal parasites is a major issue for equine clinicians. The evidence base for the recommendations for treatment and control of equine intestinal parasites is sparse, however, and few robust data exist from controlled clinical trials to validate current guidelines.

    PMID:
    14740770
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk